(Source: ONO Pharmaceutical Co Ltd) 9d344446-190a-40ae-a15c-ef6fe487bcd9.pdf July 6, 2016 European Commission approves ONGENTYS® (opicapone) a novel treatment for Parkinson´s disease patients with motor fluctuations Porto, 5 July 2016 - BIAL announced that the medicinal product ONGENTYS® (opicapone) for the treatment of adult Parkinson´s disease patients with motor fluctuations was approved by the European Commission. BIAL will make ONGENTYS® available for Parkinson's disease patients across Europe in 2016 and 2017. Opicapone is a novel once-daily, catechol-O-methyltransferase (COMT) inhibitor and is indicated as adjunctive therapy to preparations of levodopa/DOPA decarboxylase inhibitors...
↧